Patient-Reported Quality of Life Maintained With Immunotherapy for Advanced Melanoma
Source: Cancer Network, July 2019
CHICAGO—Patient-reported quality of life did not deteriorate relative to baseline in patients with advanced melanoma undergoing extended treatment with nivolumab with or without ipilimumab, according to results of the phase III CheckMate 067 study (abstract 9551) presented during a poster session at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 31–June 4 in Chicago.
“Early data from the CheckMate 067 study showed maintenance of health-related quality of life (QOL) in patients with advanced melanoma treated with nivolumab or nivolumab plus ipilimumab based on 1-year data. However, long-term health-related QOL in these patients has not yet been evaluated,” wrote the authors led by Dirk Schadendorf, of University Hospital Essen in Germany.
The study included patients from 137 sites in 21 countries and represents the first QOL results from advanced melanoma patients who underwent these immunotherapy regimens for over a 4-year period.